Lantern Pharma's ZETA AI Designs Cancer Drugs in Real-Time

ZETA AI: Transforming Drug Discovery

• 💡 ZETA AI is highlighted as a platform designed to transform drug discovery, acting as a template for the future.
• 🎯 The AI is specifically focused on solving complex problems like rare cancers, which account for a significant portion of cancer diagnoses and deaths.
• 🧠 ZETA AI is designed to think like a scientist, integrating knowledge from genomics, chemistry, dosing, manufacturing, and clinical trials.

Advanced Capabilities of ZETA AI

• 🚀 ZETA AI now includes a 24 billion parameter LLM for generating new molecules, positioning it as a drug developer rather than just an analyzer.
• 🌐 The platform hosts a self-indexed database of 560,000 clinical trials from clinicaltrials.gov, alongside curated databases and knowledge objects derived from millions of papers.
• 🧩 ZETA AI creates a knowledge graph in real-time, connecting diseases, drugs, and biomarkers, mimicking human thought processes.

Live Demonstration and Impact

• 🔬 A live demonstration showcases ZETA AI's ability to analyze 18 distinct pancreatic subtypes and access data on 438 rare cancers.
• ⏱️ The system compresses years of drug discovery into minutes, designing a full trial protocol in a process that cost approximately $20.
• ✅ The AI is presented not as a replacement for human scientists but as a tool to make them better, enabling the development of potentially hundreds of drugs per decade.

Embracing AI in Medicine

• 📈 Lantern Pharma advocates for the adoption of AI in drug development, emphasizing its role in making the process faster, cheaper, and more informed.
• 🌟 The ultimate goal is to significantly increase the rate of drug development, moving from one or two drugs a decade to potentially a hundred.